David P. Nicolau, PharmD

Director
Hartford Hospital

Disclosure(s): CARB-X: Grant/Research Support; Innoviva: Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Grant/Research Support, Honoraria; Pfizer: Advisor/Consultant, Grant/Research Support, Honoraria; Shionogi: Advisor/Consultant, Grant/Research Support, Honoraria; Venatorx: Grant/Research Support

Poster(s):

(P-1067) In Vitro Potency of Ceftibuten-Avibactam (CTB-AVI) and Comparators against Extended-Spectrum Beta-Lactamase (ESBL)-like Enterobacterales from Outpatient Centers and Nursing Homes in the United States

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1216) Comparison of the in vivo Efficacy and Resistance Development Potential between Cefiderocol (FDC) and Ceftolozane/tazobactam (C/T) Human Simulated Exposures against Pseudomonas aeruginosa in 72 Hour Murine Thigh Infection Model

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1217) Validation of Cefiderocol (FDC) Package Insert Dosing Recommendation for Patients receiving Continuous Renal Replacement Therapy (CRRT): A Prospective Multi-Center Pharmacokinetic Study

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1219) Benchmarks for Humanized Meropenem Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures Against Klebsiella pneumoniae in Standardized Murine Lung Infection Model

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1220) Humanizing Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures of Cefiderocol in Standardized Murine Lung Infection Model

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1221) Benchmark Efficacy for Humanized Cefiderocol Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures Against Gram Negative Isolates in Standardized Murine Lung Infection Model

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1226) Dose Optimization of β-lactams against Carbapenem-Resistant Pseudomonas from Turkiye Defined as Susceptible to Ceftazidime, Cefepime or Piperacillin/Tazobactam

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1227) Population Pharmacokinetics (PK) of Cefiderocol (FDC) during Acute Pulmonary Exacerbations (APE) in Adult Persons with Cystic Fibrosis (CF)

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1341) Differential Frequency of Persister cells in Clinically Derived Pseudomonas aeruginosa Isolates after Exposure to Cefiderocol (FDC) or Ceftolozane/tazobactam (C/T)

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1653) Current Prescribing Practices and Guideline Concordance for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) across Outpatient and Urgent Care Visits

Saturday, October 19, 2024
12:15 PM – 1:30 PM US PT